Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

BACKGROUND: Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was cardioprotective in this population. The objecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Raman, Subha V., Hor, Kan N., Mazur, Wojciech, He, Xin, Kissel, John T., Smart, Suzanne, McCarthy, Beth, Roble, Sharon L., Cripe, Linda H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319045/
https://www.ncbi.nlm.nih.gov/pubmed/28219442
http://dx.doi.org/10.1186/s13023-017-0590-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319045/
https://www.ncbi.nlm.nih.gov/pubmed/28219442
http://dx.doi.org/10.1186/s13023-017-0590-8

Ejemplares similares